The European Medicines Agency (EMA) backed up the FDA’s findings, as well, in their press release
on March 20. Like the FDA, the EMA warned Earuopean healthcare professionals to not go over the recommended dose of Xeljanz due to increased risk of blood clots in the lungs.
Though Pfizer and the FDA announced that they plan on reassessing Xeljanz dosage levels and infection warnings presented in the clinical trial, thousands could be impacted by the misinformed prescription information. If you or someone you care about has been injured while taking Xeljanz, you may be entitled to legal compensation through a defective product lawsuit.
Through our network of continual communication, concerned representatives, and expert lawyers, we go the extra mile to ensure your peace of mind. To AVA Law Group, Inc., you aren't just another number! Sign up today for your free case evaluation and to start taking steps towards justice and healing.